Persistent C-peptide: What does it mean?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 279-284

  Pietropaolo, Massimo ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

C peptide; GLP 1; insulin secretion; type 1 diabetes

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN;

ADVERSE OUTCOME; CELL REGENERATION; DIABETES CONTROL; DISEASE DURATION; EVIDENCE BASED MEDICINE; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN SYNTHESIS; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; PROTEIN SECRETION; REVIEW;

C-PEPTIDE; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS;

EID: 84880308677     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283628610     Document Type: Review

References (66)

1. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986; 314:1360-1368.
2. Pietropaolo M, Towns R, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med 2012; 2:; pii: a012831.
3. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008; 57:2883-2888.
4. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010; 59:2846-2853.
5. Gianani R, Campbell-Thompson M, Sarkar SA, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010; 53:690-698.
6. Steiner DF. Proinsulin and the biosynthesis of insulin. N Engl J Med 1969; 280:1106-1113.
7. Rubenstein AH, Steiner DF, Cho S, et al. Immunological properties of bovine proinsulin and related fractions. Diabetes 1969; 18:598-605.
8. Clark JL, Steiner DF. Insulin biosynthesis in the rat: demonstration of two proinsulins. Proc Natl Acad Sci USA 1969; 62:278-285.
9. Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000; 278:E759-E768.
10. Faber OK, Hagen C, Binder C, et al. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 1978; 62:197-203.
11. Steiner DF, Rubenstein AH. Proinsulin C-peptide-biological activity? Science 1997; 277:531-532.
12. Rigler R, Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA 1999; 96:13318-13323.
13. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 2012; 61:761-772.
14. \+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000; 98:283-290.
15. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October. Diabetes 2004; 53:250-264.
16. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412-419.
17. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61:2066-2073.
18. Pihoker C, Badaru A, Anderson A, et al. Insulin regimens and clinical outcomes in a type 1 diabetes cohort: the SEARCH for Diabetes in Youth study. Diabetes Care 2013; 36:27-33.
19. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. The TrialNet Natural History Study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes 2009; 10:97-104.
20. Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann N Y Acad Sci 2008; 1150:14-24.
21. Bluestone JA, Auchincloss H, Nepom GT, et al. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol 2010; 10:797-803.
22. Greenbaum CJ, Sears KL, Kahn SE, Palmer JP. Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes 1999; 48:170-175.
23. Cheung AT, Dayanandan B, Lewis JT, et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290:1959-1962.
24. Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009; 52:289-298.
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes melli-tus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993; 329:977-986.
26. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26:832-836.
27. The Diabetes Control and Complication Trial Research Group. Effect of intensive therapy on residual b-cell function in patients with type 1 diabetes in the Diabetes Control and Complication Trial. A randomized, controlled, trial Ann Int Med 1998; 128: 517-523.
28. Foulis AK, Liddle C N, Farquharson M A, et al. The histopathology of the pancreas in type (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986; 29:267-274.
29. Lohr M, Kloppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 1987; 30:757-762.
30. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009; 32:2251-2257.
31. Bottazzo GF, Dean BM, McNally JM, et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353-360.
32. Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93:12445-12450.
33. Campbell-Thompson ML, Montgomery EL, Foss RM, et al. Collection protocol for human pancreas. J Vis Exp 2012; e4039.
34. \+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005; 54:452-461.
35. Eizirik DL, Korbutt GS, Hellerstrom C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the b-cell function. J Clin Invest 1992; 90:1263-1268.
36. Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 2012; 52:1353-1361.
37. Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132:166-173.
38. Estella E, McKenzie MD, Catterall T, et al. Granzyme B-mediated death of pancreatic beta-cells requires the proapoptotic BH3-only molecule bid. Diabetes 2006; 55:2212-2219.
39. Haskins K, Kench J, Powers K, et al. Role for oxidative stress in the regeneration of islet beta cells? J Investig Med 2004; 52:45-49.
40. Santin I, Moore F, Grieco FA, et al. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apop-tosis. Cell Death Dis 2012; 3:e419.
41. Størling J, Binzer J, Andersson AK, et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005; 48:2039-2050.
42. Ott PA, Herzog BA, Quast S, et al. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin Immunol 2005; 115:102-114.
43. Anderson MS. Update in endocrine autoimmunity. J Clin Endocrinol Metab 2008; 93:3663-3670.
44. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008; 223:371-390.
45. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18-20.
46. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007; 38:112-121.
47. Atkinson MA, Gianani R. The pancreas in human type 1 diabetes: providing new answers to age-old questions. Curr Opin Endocrinol Diabetes Obes 2009; 16:279-285.
48. Cryer PE. Glucose counterregulation in man. Diabetes 1981; 30:261-264.
49. Bolli G, De Feo P, Perriello G, et al. Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia. J Clin Invest 1984; 73:917-922.
50. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26:1902-1912.
51. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87:1409-1439.
52. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14:675-688.
53. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of antiexenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14:546-554.
54. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87:1239-1246.
55. Dupré J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44:626-630.
56. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes 2011; 60:1599-1607.
57. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011; 165:77-84.
58. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes melli-tus. N Engl J Med 1992; 326:1316-1322.
59. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19:580-586.
60. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009; 5:266-275.
61. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-5158.
62. Ansarullah, Lu Y, Holstein M, et al. Stimulating beta-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. PLoS One 2013; 8:e53345.
63. Nathan DM, Cleary PA, Backlund JY, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
64. Piemonti L, Maffi P, Monti L, Bonifacio E. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011; 54:433-439.
65. Lebastchi J, Deng S, Lebastchi AH, et al. Immune therapy and b-cell death in type 1 diabetes. Diabetes 2013; 62:1676-1680.
66. Butler PC, Elashoff M, Elashoff R, Gale EA. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe? Diabetes Care 2013. [Epub ahead of print].